Hugel Inc - Asset Resilience Ratio

Latest as of December 2025: 30.56%

Hugel Inc (145020) has an Asset Resilience Ratio of 30.56% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 145020 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

₩329.07 Billion
≈ $223.01 Million USD Cash + Short-term Investments

Total Assets

₩1.08 Trillion
≈ $729.76 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Hugel Inc's Asset Resilience Ratio has changed over time. See Hugel Inc net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hugel Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Hugel Inc worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩329.07 Billion 30.56%
Total Liquid Assets ₩329.07 Billion 30.56%

Asset Resilience Insights

  • Very High Liquidity: Hugel Inc maintains exceptional liquid asset reserves at 30.56% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Hugel Inc Industry Peers by Asset Resilience Ratio

Compare Hugel Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Hugel Inc (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Hugel Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 30.56% ₩329.07 Billion
≈ $223.01 Million
₩1.08 Trillion
≈ $729.76 Million
-14.48pp
2024-12-31 45.04% ₩423.12 Billion
≈ $286.74 Million
₩939.44 Billion
≈ $636.64 Million
-6.82pp
2023-12-31 51.86% ₩481.93 Billion
≈ $326.60 Million
₩929.25 Billion
≈ $629.74 Million
+1.95pp
2022-12-31 49.91% ₩523.99 Billion
≈ $355.10 Million
₩1.05 Trillion
≈ $711.42 Million
-4.77pp
2021-12-31 54.68% ₩552.13 Billion
≈ $374.17 Million
₩1.01 Trillion
≈ $684.28 Million
-7.98pp
2020-12-31 62.66% ₩599.20 Billion
≈ $406.07 Million
₩956.34 Billion
≈ $648.10 Million
-0.92pp
2019-12-31 63.58% ₩568.80 Billion
≈ $385.47 Million
₩894.69 Billion
≈ $606.32 Million
-1.93pp
2018-12-31 65.51% ₩601.56 Billion
≈ $407.67 Million
₩918.27 Billion
≈ $622.30 Million
-7.05pp
2017-12-31 72.56% ₩595.69 Billion
≈ $403.69 Million
₩820.93 Billion
≈ $556.33 Million
+37.19pp
2016-12-31 35.38% ₩104.11 Billion
≈ $70.55 Million
₩294.30 Billion
≈ $199.44 Million
+32.29pp
2015-12-31 3.08% ₩7.20 Billion
≈ $4.88 Million
₩233.57 Billion
≈ $158.29 Million
-9.54pp
2014-12-31 12.63% ₩12.28 Billion
≈ $8.32 Million
₩97.25 Billion
≈ $65.90 Million
--
pp = percentage points

About Hugel Inc

KQ:145020 Korea Biotechnology
Market Cap
$1.85 Billion
₩2.73 Trillion KRW
Market Cap Rank
#6550 Global
#172 in Korea
Share Price
₩252500.00
Change (1 day)
-3.99%
52-Week Range
₩214000.00 - ₩388000.00
All Time High
₩388000.00
About

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more